Citations

Clear

6273 citation(s) found for "To, Andrew".

Predicting small ligand binding sites in proteins using backbone structure
Bordner, Andrew J.

Mayo Clinic

Bioinformatics | October 22, 2008 | Volume: 24 | Issue: 24 | Pages: 2865-2871

10.1093/bioinformatics/btn543 | PMID 18940825 Get It

Abstract Motivation: Specific non-covalent binding of metal ions and ligands, such as nucleotides and cofactors, is essential for the function of many proteins. Computational methods are useful for predicting the location of such binding sites when experimental information is lacking. Methods that use structural information, when available, are particularly promising since they can potentially identify non-contiguous binding motifs that cannot be found using only the amino acid sequence. Furthermore, a prediction method that can utilize low-resolution models is advantageous because high-resolution structures are available for only a relatively small fraction of proteins. Results: SitePredict is a machine learning-based method for predicting binding sites in protein structures for specific metal ions or small molecules. The method uses Random Forest classifiers trained on diverse residue-based site properties including spatial clustering of residue types and evolutionary conservation. SitePredict was tested by cross-validation on a set of known binding sites for six different metal ions and five different small molecules in a non-redundant set of protein–ligand complex structures. The prediction performance was good for all ligands considered, as reflected by AUC values of at least 0.8. Furthermore, a more realistic test on unbound structures showed only a slight decrease in the accuracy. The properties that contribute the most to the prediction accuracy of each ligand were also examined. Finally, examples of predicted binding sites in homology models and uncharacterized proteins are discussed. Availability: Binding site prediction results for all PDB protein structures and human protein homology models are available at http://sitepredict.org/. Contact: bordner.andrew@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
Stress in the ER (Endoplasmic Reticulum)
Horowitz, Jeffrey C. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 2, 2008 | Volume: 178 | Issue: 8 | Pages: 782-783

10.1164/rccm.200807-1138ed | PMID 18832553 Get It

Survival After Resection of Primary Cardiac Tumors
ElBardissi, Andrew W., Daly, Richard C. , Mullany, Charles J., Orszulak, Thomas A., Puga, Francisco J., Schaff, Hartzell V. , Dearani, Joseph A. , Schaff, Hartzell

Mayo Clinic

Circulation | September 30, 2008 | Volume: 118 | Issue: 14_suppl_1 | Pages: No page available

10.1161/circulationaha.107.783126 | PMID 18824772 Get It

Background— Primary cardiac tumors are rare but have the potential to cause significant morbidity if not treated in an appropriate and timely manner. To date, however, there have been no studies examining survival characteristics of patients who undergo surgical resection. Methods and Results— From 1957 to 2006, 323 consecutive patients underwent surgical resection of primary cardiac tumors; 163 (50%) with myxomas, 83 (26%) with papillary fibroelastomas, 18 (6%) with fibromas, 12 (4%) with lipomas, 28 (9%) with other benign primary cardiac tumors, and 19 (6%) with primary malignant tumors. Operative (30 day) mortality was 2% (n=6). Univariate analysis indicated that patients who underwent resection of fibromas and myxomas had superior survival characteristics in comparison to the remainder of tumor variants; these results were consistent after adjusting for age at surgery, year of surgery, and cardiovascular risk factors. Based on actuarial characteristics of the 2002 U.S. population, patients who underwent myxoma resection had survival characteristics that were not significantly different from that of an age and gender matched population (SMR 1.11, P =0.57) whereas those who underwent resection of fibromas (SMR 11.17, P =0.002), papillary fibroelastomas (SMR 3.17, P =0.0003), lipomas (SMR 5.0, P =0.0003), other benign tumors (SMR 4.63, P =0.003), and malignant tumors (SMR 101, P <0.0001) had significantly poorer survival characteristics. Furthermore, malignant tumors in younger patients were highly fatal (HR 0.899, P <0.0001). Although the most significant predictor of mortality was tumor histology, survival was also influenced the by the duration of CPB and NYHA III/IV; the impact of these risk factors varied with time. The cumulative incidence of myxoma recurrence was 13% and occurred in a younger population (42 versus 57 years, P =0.003) with the risk of recurrence decreased after 4 years. Conclusions— Surgical resection of primary cardiac tumors is associated with excellent long-term survival; patients with cardiac myxomas have survival characteristics that are not significantly different from that of a general population. Predictors of mortality are primarily related to tumor histology but also include clinical characteristics such as symptomatology and duration of CPB.
Clinically Applicable Models to CharacterizeBRCA1andBRCA2Variants of Uncertain Significance
Spearman, Andrew D. , Sweet, Kevin , Zhou, Xiao-Ping, McLennan, Jane, Couch, Fergus J. , Toland, Amanda Ewart

Mayo Clinic

Journal of Clinical Oncology | September 30, 2008 | Volume: 26 | Issue: 33 | Pages: 5393-5400

10.1200/jco.2008.17.8228 | PMID 18824701 Get It

PurposeTwenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7% of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making clinical management less certain. The majority of identified VUS occur only in one to two individuals; these variants are not able to be classified using current classification models with segregation analysis components.MethodsTo develop a clinically applicable method that can predict the pathogenicity of VUS that does not require familial information or segregation analysis, we identified characteristics of breast or ovarian tumors that distinguished sporadic tumors from tumors with BRCA1 or BRCA2 mutations. Study participants included individuals with known deleterious mutations in BRCA1 or BRCA2 and individuals with classified or unclassified BRCA variants.ResultsWe applied the models to 57 tumors with 43 different deleterious BRCA mutations and 57 tumors with 54 unique classified and unclassified BRCA variants. Of the 33 previously unclassified VUS studied, we found evidence of neutrality for 21.ConclusionOur models showed 98% sensitivity and 76% specificity for predicting classified DNA changes. We classified 64% of unknown variants as neutral. Classification of VUS as neutral will have immediate benefit for those individuals and their family members. These models are adaptable for the clinic and will be useful for individuals with limited available family history.
Research priorities in spasmodic dysphonia
Ludlow, Christy L. , Berke, Gerald S. , Bielamowicz, Steven , Blitzer, Andrew , Bressman, Susan , Jinnah, H. A. , Juergens, Uwe R., Martin, Sandra B., Sapienza, Christine M. , Woodson, Gayle E. , Adler, Charles H. , Hallett, Mark , Perlmutter, Joel S. , Singleton, Andrew T. , Tanner, Caroline M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | September 25, 2008 | Volume: 139 | Issue: 4 | Pages: 495-505

10.1016/j.otohns.2008.05.624 | PMID 18922334 Get It

ObjectiveTo identify research priorities to increase understanding of the pathogenesis, diagnosis, and improved treatment of spasmodic dysphonia.Study Design and SettingA multidisciplinary working group was formed that included both scientists and clinicians from multiple disciplines (otolaryngology, neurology, speech pathology, genetics, and neuroscience) to review currently available information on spasmodic dysphonia and to identify research priorities.ResultsOperational definitions for spasmodic dysphonia at different levels of certainty were recommended for diagnosis and recommendations made for a multicenter multidisciplinary validation study.ConclusionsThe highest priority is to characterize the disorder and identify risk factors that may contribute to its onset. Future research should compare and contrast spasmodic dysphonia with other forms of focal dystonia. Development of animal models is recommended to explore hypotheses related to pathogenesis. Improved understanding of the pathophysiology of spasmodic dysphonia should provide the basis for developing new treatment options and exploratory clinical trials.SignificanceThis document should foster future research to improve the care of patients with this chronic debilitating voice and speech disorder by otolaryngology, neurology, and speech pathology.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Wang, Michael , Dimopoulos, Meletios Α. , Chen, Christine , Cibeira, María Teresa , Spencer, Andrew , Rajkumar, S. Vincent , Yu, Zhinuan, Olesnyckyj, Marta, Zeldis, Jerome B. , Weber, Donna M., Attal, Michel , Knight, Robert , Rajkumar, S Vincent , Dimopoulos, Meletios A

Mayo Clinic

Blood | September 17, 2008 | Volume: 112 | Issue: 12 | Pages: 4445-4451

10.1182/blood-2008-02-141614 | PMID 18799726 Get It

Abstract This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide. Of 704 patients, 39% were thalidomide exposed. Thalidomide-exposed patients had more prior lines of therapy and longer duration of myeloma than thalidomide-naive patients. Lenalidomide + dexamethasone led to higher overall response rate (ORR), longer time to progression (TTP), and progression-free survival (PFS) versus placebo + dexamethasone despite prior thalidomide exposure. Among lenalidomide + dexamethasone-treated patients, ORR was higher in thalidomide-naive versus thalidomide-exposed patients (P = .04), with longer median TTP (P = .04) and PFS (P = .02). Likewise for dexamethasone alone-treated patients (P = .03 for ORR, P = .03 for TTP, P = .06 for PFS). Prior thalidomide did not affect survival in lenalidomide + dexamethasone-treated patients (36.1 vs 33.3 months, P > .05). Thalidomide-naive and thalidomide-exposed patients had similar toxicities. Lenalidomide + dexamethasone resulted in higher rates of venous thromboembolism, myelosuppression, and infections versus placebo + dexamethasone, independent of prior thalidomide exposure. Lenalido-mide + dexamethasone was superior to placebo + dexamethasone, independent of prior thalidomide exposure. Although prior thalidomide may have contributed to inferior TTP and PFS compared with thalidomide-naive patients, these parameters remained superior compared with placebo + dexamethasone; similar benefits compared with placebo + dexamethasone were not evident for thalidomide-exposed patients in terms of overall survival. Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047.
Systems Approach to Understanding Electromechanical Activity in the Human Heart
Rudy, Yoram , Ackerman, Michael J. , Bers, Donald M. , Clancy, Colleen E. , Houser, Steven R. , London, Barry , McCulloch, Andrew D. , Przywara, Dennis A., Rasmusson, Randall L. , Solaro, R. John , Trayanova, Natalia A. , Wagoner, David R. Van , Varró, András , Weiss, James N. , Lathrop, David A. , Trayanova, Natalia A , London, Barry

Mayo Clinic

Circulation | September 8, 2008 | Volume: 118 | Issue: 11 | Pages: 1202-1211

10.1161/circulationaha.108.772715 | PMID 18779456 Get It

The National Heart, Lung, and Blood Institute (NHLBI) convened a workshop of cardiologists, cardiac electrophysiologists, cell biophysicists, and computational modelers on August 20 and 21, 2007, in Washington, DC, to advise the NHLBI on new research directions needed to develop integrative approaches to elucidate human cardiac function. The workshop strove to identify limitations in the use of data from nonhuman animal species for elucidation of human electromechanical function/activity and to identify what specific information on ion channel kinetics, calcium handling, and dynamic changes in the intracellular/extracellular milieu is needed from human cardiac tissues to develop more robust computational models of human cardiac electromechanical activity. This article summarizes the workshop discussions and recommendations on the following topics: (1) limitations of animal models and differences from human electrophysiology, (2) modeling ion channel structure/function in the context of whole-cell electrophysiology, (3) excitation–contraction coupling and regulatory pathways, (4) whole-heart simulations of human electromechanical activity, and (5) what human data are currently needed and how to obtain them. The recommendations can be found on the NHLBI Web site at http://www.nhlbi.nih.gov/meetings/workshops/electro.htm.
In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46
Wang, Hongjie , Liu, Ying , Li, Zong-Yi, Tuve, Sebastian, Stone, Daniel , Kalyushniy, Oleksandr, Shayakhmetov, Dmitry M. , Verlinde, Christophe L. M. J. , Stehle, Thilo , McVey, John H. , Baker, Andrew H. , Peng, Kah-Whye , Roffler, Steve R. , Lieber, André , Baker, Andrew H

Mayo Clinic

Journal of Virology | August 28, 2008 | Volume: 82 | Issue: 21 | Pages: 10567-10579

10.1128/jvi.01308-08 | PMID 18753195 Get It

ABSTRACT Gene transfer vectors containing adenovirus (Ad) serotype 35 (Ad35) fibers have shown promise for cancer and stem cell gene therapy. In this study, we attempted to improve the in vitro and in vivo infection properties of these vectors by increasing their affinity to the Ad35 fiber receptor CD46. We constructed Ad vectors containing either the wild-type Ad35 fiber knob (Ad5/35) or Ad35 knob mutants with 4-fold- and 60-fold-higher affinity to CD46 (Ad5/35+ and Ad5/35++, respectively). In in vitro studies with cell lines, the higher affinities of Ad5/35+ and Ad5/35++ to CD46 did not translate into correspondingly higher transduction efficiencies, regardless of the CD46 receptor density present on cells. However, in vivo, in a mouse model with preestablished CD46 high liver metastases, intravenous injection of Ad5/35++ resulted in more-efficient tumor cell transduction. We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection.
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007
Bronstein, Jeff M. , Carvey, Paul M., Chen, Honglei , Cory‐Slechta, Deborah A. , Monte, Donato A. Di , Duda, John E. , English, Paul , Goldman, Samuel M. , Grate, Stephen J., Hoppin, Jane A. , Jewell, Sarah A. , Kamel, Freya , Langston, J. William, Logroscino, Giancarlo , Nelson, Lorene M. , Ravina, Bernard, Rocca, Walter A. , Ross, G. Webster, Schettler, Ted, Schwarzschild, Michael A. , Scott, Bill, Seegal, Richard F., Singleton, Andrew , Steenland, Kyle , Eeden, Stephen Van Den, Weisskopf, Marc G. , Hansen, Johnni , Koroshetz, Walter J. , Tanner, Caroline M. , Logroscino, Giancarlo

Mayo Clinic

Environmental Health Perspectives | August 25, 2008 | Volume: 117 | Issue: 1 | Pages: 117-121

10.1289/ehp.11702 | PMID 19165397 Get It

Abstract Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder. People with PD, their families, scientists, health care providers, and the general public are increasingly interested in identifying environmental contributors to PD risk. Methods In June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, USA, to assess what is known about the contribution of environmental factors to PD. Results We describe the conclusions around which they came to consensus with respect to environmental contributors to PD risk. We conclude with a brief summary of research needs. Conclusions PD is a complex disorder, and multiple different pathogenic pathways and mechanisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, and within populations, the causes of PD are heterogeneous. Although rare recognized genetic mutations are sufficient to cause PD, these account for &lt; 10% of PD in the U.S. population, and incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay among environmental factors and genetic makeup likely influences the risk of developing PD. There is a need for further understanding of how risk factors interact, and studying PD is likely to increase understanding of other neurodegenerative disorders.